Literature DB >> 266734

Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins.

S H Appel, R Anwyl, M W McAdams, S Elias.   

Abstract

Altered geometry of the neuromuscular junction and a decreased number of acetylcholine receptors appear responsible for the defect of neuromuscular transmission in myasthenia gravis. We have used cultured rat myotubes as a model to study in vitro the potential role of myasthenic globulins in the pathological process. Acetylcholine receptor content was assayed by the extent of 125I-labeled alpha-bungarotoxin binding, and acetylcholine receptor function was assayed by the sensitivity to acetylcholine iontophoresis. The half-life of the acetylcholine receptor was 18.5 hr in the presence or absence of control sera. Myasthenic sera and globulins produced a gradual reduction in acetylcholine receptors, as assessed by biochemical and electrophysiological techniques. The half-life in the presence of myasthenic sera was 6 hr. The accelerated turnover was unaffected by puromycin but was slowed by lowered temperature (18-20 degrees), interference with energy metabolism (2,4-dinitrophenol), and interference with cytoskeletal structures (colchicine and cytochalasin B). We found no electrophysiological evidence to suggest globulin blockade of acetylcholine access to the acetylcholine receptor. Our observations suggest that circulating globulins in myasthenia gravis may contribute to the functional defects of neuromuscular transmission by accelerating the rate of internationalization and degradation of surface membrane acetylcholine receptors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266734      PMCID: PMC431089          DOI: 10.1073/pnas.74.5.2130

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Acetylcholine receptor degradation measured by pulse chase labelling.

Authors:  J P Merlie; J P Changeux; F Gros
Journal:  Nature       Date:  1976-11-04       Impact factor: 49.962

2.  An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.

Authors:  E X Albuquerque; J E Rash; R F Mayer; J R Satterfield
Journal:  Exp Neurol       Date:  1976-06       Impact factor: 5.330

3.  An immunologically induced defect of neuromuscular transmission in rats and rabbits.

Authors:  D B Sanders; L S Schleifer; M E Eldefrawi; N L Norcross; E E Cobb
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

4.  The dynamic state of the lymphocyte membrane. Factors affecting the distribution and turnover of surface immunoglobulins.

Authors:  F Loor; L Forni; B Pernis
Journal:  Eur J Immunol       Date:  1972-06       Impact factor: 5.532

5.  Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

Authors:  R R Almon; C G Andrew; S H Appel
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

6.  Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction.

Authors:  A N Bender; S P Ringel; W K Engel; M P Daniels; Z Vogel
Journal:  Lancet       Date:  1975-03-15       Impact factor: 79.321

7.  Loss of alpha-bungarotoxin from junctional and extrajunctional acetylcholine receptors in rat diaphragm muscle in vivo and in organ culture.

Authors:  D K Berg; Z W Hall
Journal:  J Physiol       Date:  1975-11       Impact factor: 5.182

8.  Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man.

Authors:  J S Flier; C R Kahn; D B Jarrett; J Roth
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

9.  Ligand-induced movement of lymphocyte membrane macromolecules. 3. Relationship between the formation and fate of anti-Ig-surface Ig complexes and cell metabolism.

Authors:  E R Unanue; M J Karnovsky; H D Engers
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

10.  Acetylcholine receptor turnover in membranes of developing muscle fibers.

Authors:  P N Devreotes; D M Fambrough
Journal:  J Cell Biol       Date:  1975-05       Impact factor: 10.539

View more
  33 in total

1.  Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.

Authors:  I Kaplan; B T Blakely; G K Pavlath; M Travis; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Authors:  Simon N Fewou; Angie Rupp; Lauren E Nickolay; Kathryn Carrick; Kay N Greenshields; John Pediani; Jaap J Plomp; Hugh J Willison
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 3.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 4.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 5.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

6.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

7.  Regulation of acetylcholine receptor levels by a cholinergic agonist in mouse muscle cell cultures.

Authors:  M D Noble; T H Brown; J H Peacock
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

8.  Inhibition of methyltransferase reduces the turnover of acetylcholine receptors.

Authors:  R W Kuncl; D B Drachman; R Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Acetylcholine receptor and thymus in experimental autoimmune myasthenia gravis and experimental myositis.

Authors:  S Ueno; K Wada; J Kang; M Takahashi; S Tarui
Journal:  Clin Exp Immunol       Date:  1982-12       Impact factor: 4.330

10.  A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

Authors:  C W Olanow; A S Wechsler; A D Roses
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.